PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2025-09-02

Date Title Company
02-Sep-2025 Aera Therapeutics Appoints Bill Querbes, Ph.D., as Chief Scientific Officer Businesswire
02-Sep-2025 Neucore Bio Awarded U.S. National Institutes of Health (NIH) STTR Phase I Grant to Pursue Exosome-based Genetic Medicine for Charcot-Marie-Tooth Disease Type 1A (CMT1A) Businesswire
02-Sep-2025 Silence Therapeutics to Participate in September Investor Conferences Businesswire
02-Sep-2025 Lineage Cell Therapeutics to Present at September 2025 Investor Conferences Businesswire
02-Sep-2025 OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference Businesswire
02-Sep-2025 Thermo Fisher Scientific Completes Acquisition of Solventum’s Purification and Filtration Business Businesswire
02-Sep-2025 Agilent’s MMR IHC Panel pharmDx (Dako Omnis) Receives European IVDR Certification as a Companion Diagnostic Test for Colorectal Cancer Businesswire
02-Sep-2025 Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina Businesswire
02-Sep-2025 Encoded Therapeutics Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for ETX101 in SCN1A+ Dravet Syndrome Businesswire
02-Sep-2025 United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis Businesswire
02-Sep-2025 Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome Businesswire
02-Sep-2025 Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference Businesswire
02-Sep-2025 Merck’s Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate Met All Primary and Key Secondary Endpoints in Adults with Hypercholesterolemia in Pivotal CORALreef Lipids Study Businesswire
02-Sep-2025 Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference Businesswire
02-Sep-2025 Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder Businesswire
02-Sep-2025 ICON plc to Participate at Upcoming Investor Conferences Businesswire
02-Sep-2025 US Food and Drug Administration (FDA) Approves Henlius and Organon’s BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively Businesswire
02-Sep-2025 Mainz Biomed Announces Registration of ColoAlert in the United Kingdom Mainz BioMed N.V.
02-Sep-2025 Releaf Acquires Domain Releaf.com for £110,000 ACCESS Newswire
02-Sep-2025 Releaf Acquires Domain Releaf.com for £110,000 ACCESS Newswire